



Effect of Von Willebrand Antigen on Mortality and Major Adverse Cardiac Events in Diabetic and Non-diabetic Patients with Anterior ST Elevated Myocardial Infarction

Seyed Masoud Seyedian¹, Fatemeh Soltani¹, Najmaldin Saki², Golshan Afshari² and Habib Haybar^{3,*}

¹Department of Cardiology, Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

²Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

³Department of Cardiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Department of Cardiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: takamoolsk@yahoo.com

Received 2019 October 14; Revised 2020 January 08; Accepted 2020 January 21.

Abstract

Background: Coronary Artery Disease (CAD) is one of the main causes of mortality in the world. The role of Von Willebrand Factor (VWF) is very important in platelet adhesion, microcirculation, and acute stenosis and it contributes to the development of atherothrombotic processes.

Objectives: We decided to evaluate the level of VWF in diabetic and non-diabetic patients as an effective factor in CAD.

Methods: This study was performed on 65 patients (32 diabetic patients and 33 non-diabetic patients), who referred to an Echocardiography and Angiography Department. They were evaluated for the VWF level, blood group, and fasting blood glucose. Patients underwent echocardiography, angiography, and, if necessary, percutaneous coronary intervention (PCI) during the hospitalization. They also underwent coronary artery bypass grafting (CABG) if they needed the surgery. After 40 days, we evaluated the anterior ST-elevation myocardial infarction (STEMI), mortality, major adverse cardiac events (MACE), heart failure, and limb ischemia.

Results: The VWF level was significantly higher in diabetic patients ($P < 0.0001$). Also, the increased VWF levels were significantly more frequent in diabetic patients under CABG than in non-diabetic patients under CABG ($P = 0.013$). There was a significant relationship between positive MACE and increased VWF levels.

Conclusions: The level of VWF in diabetic patients increases cardiovascular problems. Therefore, it seems that these patients can benefit from VWF-reducing drugs. Clinical research can be promising in this field.

Keywords: Cardiovascular Diseases, Myocardial Infarction, Percutaneous Coronary Intervention, Von Willebrand Factor, Diabetes

1. Background

Coronary Artery Disease (CAD) is one of the main causes of mortality and morbidity in the general population. It is estimated that CAD contributes to nearly 50% of annual mortality. It is characterized by atherosclerosis in epicardial coronary arteries (1). Atherosclerotic plaques are the main features of atherosclerosis that progressively narrow the coronary artery lumen and hence disrupt myocardial blood flow. Based on the severity of obstruction and the rate of development, it may also cause myocardial infarction (MI) (2). The incidence of CAD has increased due to increased obesity and other CVD risk factors. Studies showed that the prevalence rates of CAD, coronary diseases-associated risk factors, and metabolic syndromes are higher in Iran than in Western countries (3, 4). One of the most important risk factors for CAD is diabetes, and

many studies have confirmed the association between CAD and type 2 diabetes mellitus (5-7). The prevalence of type 2 diabetes mellitus (T2DM) in the Iranian population was reported to be 5.5% (8). It is estimated that diabetic-related CVD is up to 400 per 100,000 population in Iran (9). Esteghamati et al. indicated that 30% of patients with the acute coronary syndrome in Iran were DM patients (10).

Von Willebrand Factor (VWF) is a large glycoprotein that is produced as a multimeric complex in megakaryocytes and endothelial cells (11). The role of VWF is very important in platelet adhesion in high shear rates, microcirculation, and acute stenosis and it contributes to atherothrombotic development (12). The plasma levels of VWF can vary in different people. It is affected by genetic factors such as the ABO blood group and non-genetic factors such as sex hormones and inflammatory mediators. There are several factors, such as hypertension, inflam-

matory mediators, and factors affecting vascular tonicity (thrombin, histamine-anion superoxide, epinephrine, and vasopressin) that induce endothelial cells to release VWF. The normal range of VWF has been reported from 50 to 160 IU/dL. The active form of VWF increases during inflammation. The severity of inflammation is affected by insulin resistance conditions such as glucose intolerance, diabetes, and obesity. Therefore, glucose impairment may indirectly affect the plasma level of VWF (13). Two key points in the pathophysiology of atherothrombosis are endothelial dysfunction and chronic vascular wall inflammation. The increased VWF level represents the endothelial dysfunction, which can be involved in the development of cardiovascular disorders (14).

2. Objectives

In this study, we mean to elucidate the prognostic value of VWF in diabetic CAD patients.

3. Methods

3.1. Study Design

In this descriptive-analytical study, we included diabetic CAD patients who had been referred to the Golestan Hospital Angiography Department in 2018. We excluded patients with arterial fibrillation, frequent premature beats, left bundle branch block, severe valvular disease, and history of previous cardiac surgery. The study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences. Signed informed consent forms were obtained from participants.

3.2. Measurements

For each patient, three blood samples were collected. A sample containing Trisodium citrate was used to measure the VWF antigen, which was centrifuged at 2,000 - 2,500 rpm for 15 min and plasma was stored at -80°C until evaluation. An EDTA specimen for CBC, BG was considered. The last sample was used for BS assessment. Patients were examined by CAG and echocardiography. Afterward, the patients were managed by PCI or CABG.

3.3. Von Willebrand Factor Antigen Measurement

Human Von Willebrand Factor (VWF) in vitro enzyme-linked immunosorbent assay (ELISA) kit (ab189571) SimpleStep ELISA® range was used for the quantitative measurement of VWF in plasma. A VWF specific antibody was precoated onto 96-well plates and blocked. Standard or test samples were added to the wells and subsequently, a VWF specific biotinylated detection antibody

was added, followed by washing with wash buffer. The streptavidin-peroxidase conjugates were added and unbound conjugates were washed away with wash buffer. 3,3',5,5'-Tetramethylbenzidine (TMB) was then used to visualize the streptavidin-peroxidase enzymatic reaction. TMB was catalyzed by streptavidin-peroxidase to produce a blue color product that changed into yellow after adding the acidic stop solution. The density of yellow coloration was directly proportional to the amount of VWF captured on the plate.

3.4. Outcomes

Forty days after anterior STEMI, echocardiography was repeated and MACE (CVA, heart failure, mortality, and limb ischemia) was evaluated on the same day.

3.5. Statistical Analysis

All data were analyzed by descriptive statistics including mean, standard deviation, and frequency. The mean levels were compared using the Student's independent *t* test or Mann-Whitney test according to data distribution. The chi-square test was used for comparing the proportions. All statistical analyses were carried out using SPSS version 19. A *P* value of less than 0.05 was considered significant.

4. Results

In this study, we examined 65 patients with a mean age of 59 years (59.4 ± 6.47) in the range of 42 - 69 years. Patient characteristics are summarized in Table 1. Accordingly, 49.2% ($n=32$) of the patients had diabetes. Also, more than 93% ($n=61$) of the patients had a cerebrovascular accident (CVA). The limb ischemia was seen in only one (4.6%) patient (Table 1). Angiography reports and the intervention procedures on STEMI patients are presented in Table 2. Most patients were SVD ($n=29$, 44.6%), followed by 2VD ($n=19$, 29.2%) and 3VD ($n=17$, 26.2%). Of the 65 patients studied, 36 (55.4%) patients were on percutaneous coronary intervention (PCI) treatment and 13 (20%) patients were treated with CABG. The rest of the patients ($n=16$) did not receive any interventions. The comparison of the studied variables between diabetic and non-diabetic patients showed that although there was no significant difference in terms of mean age, sex distribution, ABO blood group, and the history of smoking, the frequency of increased VWF levels was significantly higher in diabetic patients than in non-diabetic patients ($P < 0.0001$). The mean level of EF was significantly lower in diabetic patients while there was no significant relationship between diabetes and CAG results.

Treatment procedures did not show any significant differences between diabetic and non-diabetic patients (Table 3). The incidence of multivessel involvement was significantly ($P = 0.04$) higher in patients with an increased level of VWF. Moreover, the MACE was significantly associated with the VWF levels (Table 4).

Table 1. Patients Characteristics

Variables	Frequency	Percent
DM		
No	33	50.8
Yes	32	49.2
Gender		
Female	32	49.2
Male	33	50.8
Rh		
Neg	15	23.1
Pos	50	76.9
BG		
A	23	35.4
B	18	27.7
AB	6	9.2
O	18	27.7
Smoker		
No	59	90.8
Yes	6	9.2
Mortality		
No	62	95.4
Yes	3	4.6
Limb ischemia		
No	64	98.5
Yes	1	1.5
VWF		
Low	27	41.5
Intermediate	11	16.9
High	27	41.5

Abbreviations: BG, blood group; DM, diabetes mellitus; VWF, Von Willebrand Factor

5. Discussion

The findings of this study showed that the incidence of CAD, the number of involved vessels, and the impairment of cardiac pacemaker function were higher in patients with DM (15). Our results are in line with previous

Table 2. Angiography Reports and Intervention Procedures

Interventions	Frequency	Percent
CAG		
SVD	29	44.6
2VD	19	29.2
3VD	17	26.2
PCI		
No	29	44.6
Yes	36	55.4
CABG		
No	52	80.0
Yes	13	20.0

Abbreviations: CAG, coronary angiography; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention

Table 3. Comparison Variables in Diabetic and Non-diabetic Patients^a

Variables	Diabetic	Non-diabetic	P Value
Age	57.94 ± 6.49	60.82 ± 6.2	0.07
Gender, Male	17 (53.1)	16 (48.5)	0.708
Smoker	1 (3.1)	5 (15.2)	
Blood group			
A	13 (40.6)	10 (30.3)	0.185
B	11 (34.4)	7 (21.2)	
AB	3 (9.4)	3 (9.1)	
O	5 (15.6)	13 (39.4)	
Von Willebrand Factor			
Low	9 (28.1)	29 (87.9)	< 0.0001
High	23 (71.9)	4 (12.1)	
CAG			
Single vessel	7 (21.9)	22 (66.7)	0.001
Two vessels	14 (43.8)	5 (15.2)	
Three vessels	11 (34.4)	6 (18.2)	
Ejection fraction	34.69 ± 7.82	41.97 ± 7.28	< 0.0001
Interventions			
PCI	13 (40.6)	16 (48.5)	0.52
CABG	7 (21.9)	6 (18.2)	0.71
Limb Ischemia	1 (3.1)	0	0.3
Mortality	2 (6.3)	1 (3)	0.53

Abbreviations: CAG, coronary angiography; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention

^aValues are expressed as mean ± SD or No. (%)

studies conducted by Natali et al. who found that abnormal coronary arteries were more frequent in DM than in

Table 4. Correlation Between VWF and Patient Outcome

Variables	VWF Level, No. (%)		P Value
	Low	High	
Intervention type			0.7
No intervention	12 (66.7)	6 (33.3)	
PCI	2 (58.8)	14 (41.2)	
CABG	5 (45.5)	6 (54.5)	
PCI + CABG	1 (50)	1 (50)	
CAG			0.045
Single vessel	4 (57.1)	3 (42.9)	
Multi-vessels	5 (20)	20 (80)	
MACE			0.022
Positive	13 (43.3)	17 (56.7)	
Negative	25 (71.4)	10 (28.6)	

Abbreviations: CABG, coronary artery bypass grafting; CAG, coronary angiography; MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention

non-DM patients and in a study of a large group of patients, the patients also showed a higher prevalence of the three-vessel disease among DM patients (16). Similar findings were also reported by Gui et al. (17) in Chinese people and by Uddin et al. (18). However, Cariou et al. (19) failed to find significant differences in multivessel involvement between DM and non-DM patients. However, there is a controversy concerning whether the angiographic results are different in DM and non-DM patients and our results indicated the involvement of diabetes-related risk factors in CAD development. Moreover, a prospective study found that DM patients were at least two times more susceptible to CHD and its related mortality than non-DM patients (17). The etiology of this higher frequency of CHD-related morbidity and mortality among DM patients is not completely explained. Although many CHD-related risk factors (e.g., dyslipidemia, hypertension, overweight, etc.) are more frequent in DM, they could only explain a small part of CHD susceptibility.

We found that diabetic patients had higher levels of VWF. The same results have been previously shown by other studies. A study conducted by Shao et al. showed that the serum levels of VWF were significantly higher in patients with type 2 DM than in normal subjects (18). Moreover, Seligman et al. showed a significant increase in serum VWF in DM patients, especially those with impaired lipid profiles (19). It will be more important when we know the role of VWF serum level in developing cardiovascular disorders. In a meta-analysis conducted by Whincup et al., it was suggested that the increased levels of VWF were associated with the increase of CVD and the association be-

tween VWF and the incidence of CVD was stronger in high-risk populations, such as diabetic patients, than in non-diabetic people. Frankel et al. conducted a study on 3,799 patients and showed the relationship between increased VWF serum level and the risk of CVD in diabetic patients. They also proposed the VWF as a unique CVD risk factor in DM patients.

5.1. Conclusions

In this study, we found a strong correlation between MACE and VWF levels. Based on this study, VWF is not only involved in CVD development but also may be actively involved in the progression of CVD. Collectively, our findings are in line with previous studies that showed the importance of VWF serum level in diabetes-related cardiovascular disorders. We also found the prognostic role of VWF in predicting MACE in DM patients. The low sample size and lack of evaluating other major CVD-associated risk factors were the main limitations of this study.

Acknowledgments

We wish to thank all our colleagues at Imam Khomeini Hospital, Ahvaz, Iran.

Footnotes

Conflict of Interests: The authors declare that they have no conflict of interest.

Ethical Approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Local Ethics Committee of Tehran University of Medical Sciences and with the 1964 Helsinki Declaration.

Funding/Support: None.

Informed Consent: Written informed consent was obtained from all patients and normal individuals.

References

- Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri Kashani A. Prevalence of coronary artery disease risk factors in Iran: A population based survey. *BMC Cardiovasc Disord.* 2007;7:32. doi: [10.1186/1471-2261-7-32](https://doi.org/10.1186/1471-2261-7-32). [PubMed: [17971195](https://pubmed.ncbi.nlm.nih.gov/17971195/)]. [PubMed Central: [PMC2200651](https://pubmed.ncbi.nlm.nih.gov/PMC2200651/)].
- Haybar H, Zayeri ZD. The value of using polymorphisms in anti-platelet therapy. *Front Biol.* 2017;12(5):349–56. doi: [10.1007/s11515-017-1456-0](https://doi.org/10.1007/s11515-017-1456-0).
- Ebrahimi M, Kazemi-Bajestani SM, Ghayour-Mobarhan M, Ferns GA. Coronary artery disease and its risk factors status in Iran: A review. *Iran Red Crescent Med J.* 2011;13(9):610–23. doi: [10.5812/kowsar.20741804.2286](https://doi.org/10.5812/kowsar.20741804.2286). [PubMed: [24069531](https://pubmed.ncbi.nlm.nih.gov/24069531/)]. [PubMed Central: [PMC3779358](https://pubmed.ncbi.nlm.nih.gov/PMC3779358/)].

4. Haybar H, Parsa SA, Khareshi I, Zayeri ZD. Pentraxin level is the key to determine primary percutaneous coronary intervention (PCI) or fibrinolysis. *Cardiovasc Hematol Disord Drug Targets*. 2019;**19**(2):160–8. doi: [10.2174/1871529X19666181120161810](https://doi.org/10.2174/1871529X19666181120161810). [PubMed: [30465517](https://pubmed.ncbi.nlm.nih.gov/30465517/)].
5. Haybar H, Jalali MT, Zayeri ZD. What genetics tells us about cardiovascular disease in diabetic patients? *Cardiovasc Hematol Disord Drug Targets*. 2018;**18**(2):147–52. doi: [10.2174/1871529X18666180212114305](https://doi.org/10.2174/1871529X18666180212114305). [PubMed: [29437019](https://pubmed.ncbi.nlm.nih.gov/29437019/)].
6. Shogade TT, Essien IO, Ekrikpo UE, Umoh IO, Utin CT, Unadike BC, et al. Clinical and echocardiographic determinants of heart disease in uncomplicated type II Nigerian diabetic patients. *Nigerian J Cardiol*. 2018;**15**(1):1.
7. Naito R, Kasai T. Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. *World J Cardiol*. 2015;**7**(3):119–24. doi: [10.4330/wjcv.v7.i3.119](https://doi.org/10.4330/wjcv.v7.i3.119). [PubMed: [25810811](https://pubmed.ncbi.nlm.nih.gov/25810811/)]. [PubMed Central: [PMC4365308](https://pubmed.ncbi.nlm.nih.gov/PMC4365308/)].
8. Azimi-Nezhad M, Ghayour-Mobarhan M, Parizadeh MR, Safarian M, Esmaeili H, Parizadeh SM, et al. Prevalence of type 2 diabetes mellitus in Iran and its relationship with gender, urbanisation, education, marital status and occupation. *Singapore Med J*. 2008;**49**(7):571–6. [PubMed: [18695867](https://pubmed.ncbi.nlm.nih.gov/18695867/)].
9. Abegunde DO, Mathers CD, Adam T, Ortegón M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. *Lancet*. 2007;**370**(9603):1929–38. doi: [10.1016/S0140-6736\(07\)61696-1](https://doi.org/10.1016/S0140-6736(07)61696-1). [PubMed: [18063029](https://pubmed.ncbi.nlm.nih.gov/18063029/)].
10. Esteghamati A, Abbasi M, Nakhjavani M, Yousefizadeh A, Basa AP, Afshar H. Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. *Cardiovasc Diabetol*. 2006;**5**:15. doi: [10.1186/1475-2840-5-15](https://doi.org/10.1186/1475-2840-5-15). [PubMed: [16842631](https://pubmed.ncbi.nlm.nih.gov/16842631/)]. [PubMed Central: [PMC1550715](https://pubmed.ncbi.nlm.nih.gov/PMC1550715/)].
11. Wibowo A, Jayarajan V, Vanhaverbeke M, Veltman D, Trenson S, Gillijns H, et al. P2567 Angiogenic and cytoprotective potential of exosomes derived from blood outgrowth endothelial cells in ischemic heart disease. *Euro Heart J*. 2017;**38**(suppl_1). doi: [10.1093/eurheartj/ehx502.P2567](https://doi.org/10.1093/eurheartj/ehx502.P2567).
12. Rusu L, Minshall RD. Endothelial cell von willebrand factor secretion in health and cardiovascular disease. *Endothelial Dysfunction*. 2018;**147**. doi: [10.5772/intechopen.74029](https://doi.org/10.5772/intechopen.74029).
13. Wolters FJ, Boender J, de Vries PS, Sonneveld MA, Koudstaal PJ, de Maat MP, et al. Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: A population-based study. *Sci Rep*. 2018;**8**(1):5474. doi: [10.1038/s41598-018-23865-7](https://doi.org/10.1038/s41598-018-23865-7). [PubMed: [29615758](https://pubmed.ncbi.nlm.nih.gov/29615758/)]. [PubMed Central: [PMC5882924](https://pubmed.ncbi.nlm.nih.gov/PMC5882924/)].
14. American Diabetes Association. 8. Cardiovascular disease and risk management. *Diabetes Care*. 2016;**39** Suppl 1:S60–71. doi: [10.2337/dc16-S011](https://doi.org/10.2337/dc16-S011). [PubMed: [26696684](https://pubmed.ncbi.nlm.nih.gov/26696684/)].
15. Rajaei E, Haybar H, Mowla K, Zayeri ZD. Metformin one in a million efficient medicines for rheumatoid arthritis complications: Inflammation, osteoblastogenesis, cardiovascular disease, malignancies. *Curr Rheumatol Rev*. 2019;**15**(2):116–22. doi: [10.2174/1573397114666180717145745](https://doi.org/10.2174/1573397114666180717145745). [PubMed: [30019648](https://pubmed.ncbi.nlm.nih.gov/30019648/)].
16. Natali A, Vichi S, Landi P, Severi S, L'Abbate A, Ferrannini E. Coronary atherosclerosis in Type II diabetes: Angiographic findings and clinical outcome. *Diabetologia*. 2000;**43**(5):632–41. doi: [10.1007/s001250051352](https://doi.org/10.1007/s001250051352). [PubMed: [10855538](https://pubmed.ncbi.nlm.nih.gov/10855538/)].
17. Gui MH, Qin GY, Ning G, Hong J, Li XY, Lu AK, et al. The comparison of coronary angiographic profiles between diabetic and nondiabetic patients with coronary artery disease in a Chinese population. *Diabetes Res Clin Pract*. 2009;**85**(2):213–9. doi: [10.1016/j.diabres.2009.05.010](https://doi.org/10.1016/j.diabres.2009.05.010). [PubMed: [19501926](https://pubmed.ncbi.nlm.nih.gov/19501926/)].
18. Uddin SN, Malik F, Bari MA, Siddiqui NI, Khan GK, Rahman S, et al. Angiographic severity and extent of coronary artery disease in patients with type 2 diabetes mellitus. *Mymensingh Med J*. 2005;**14**(1):32–7. [PubMed: [15695951](https://pubmed.ncbi.nlm.nih.gov/15695951/)].
19. Cariou B, Bonnevie L, Mayaudon H, Dupuy O, Ceccaldi B, Bauduceau B. Angiographic characteristics of coronary artery disease in diabetic patients compared with matched non-diabetic subjects. *Diabetes Nutr Metab*. 2000;**13**(3):134–41. [PubMed: [10963389](https://pubmed.ncbi.nlm.nih.gov/10963389/)].